Pancreatic Cancer Research

ResearcherConsejo Nacional de Investigaciones Científicas y TécnicasActive in the last 2 years

Eduardo Chuluyán

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-3084-2500; OpenAlex author ID A5013355210. Sources: OpenAlex.

Their work

Papers
9
Trials
0
Grants
0
Labs led
0
Collaborators
30
Papers, trials and grants by year

2015: 1 paper · 2016: none · 2017: none · 2018: none · 2019: none · 2020: 1 paper · 2021: 2 papers · 2022: 1 paper · 2023: 1 paper · 2024: none · 2025: 1 paper · 2026: 2 papers

Papers 9

  1. Stage-resolved gene drivers of pancreatic ductal adenocarcinoma progression and therapeutic vulnerabilities. Co-author DOI 10.1016/j.isci.2026.115164↗
  2. Pathway-driven therapeutic stratification in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.tranon.2026.102920↗
  3. KRAS inhibition reverses chemotherapy resistance promoted by therapy-induced senescence-like in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.tranon.2025.102421↗
  4. [The mRNA vaccine for the treatment of pancreatic cancer is here to stay]. Co-author PMID 37582144↗
  5. Inhibition of glucuronidation in pancreatic cancer improves gemcitabine anticancer activity. Co-author DOI 10.1002/cac2.12365↗
  6. Targeting REG3β limits pancreatic ductal adenocarcinoma progression through CTGF downregulation. Co-author DOI 10.1016/j.canlet.2021.08.024↗
  7. Squamousness gain defines pancreatic ductal adenocarcinoma hepatic metastases phenotype, and gemcitabine response. Co-author DOI 10.1016/j.ejca.2021.06.038↗
  8. Evidencing a Pancreatic Ductal Adenocarcinoma Subpopulation Sensitive to the Proteasome Inhibitor Carfilzomib. Co-author DOI 10.1158/1078-0432.ccr-20-1232↗
  9. IL17 Functions through the Novel REG3β-JAK2-STAT3 Inflammatory Pathway to Promote the Transition from Chronic Pancreatitis to Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-15-0896↗

Closest collaborators

The 25 strongest of 30 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Juan Iovanna · 9 shared papers, 2015–2026 · strength 1.39
  2. Nicolas Alejandro Fraunhoffer · 8 shared papers, 2020–2026 · strength 1.35
  3. Nelson Dusetti · 7 shared papers, 2020–2026 · strength 1.20
  4. Analía Meilerman Abuelafia · 6 shared papers, 2020–2026 · strength 0.99
  5. Daniel Grasso · 4 shared papers, 2023–2026 · strength 0.81
  6. Brice Chanez · 3 shared papers, 2022–2026 · strength 0.58
  7. Oscar Mazza · 3 shared papers, 2023–2026 · strength 0.57
  8. María Eugenia Pasqualini · 3 shared papers, 2023–2026 · strength 0.57
  9. María Noé Garcia · 3 shared papers, 2023–2026 · strength 0.57
  10. Agustín Yaneff · 3 shared papers, 2023–2026 · strength 0.57
  11. Daniela Laura Papademetrio · 3 shared papers, 2023–2026 · strength 0.57
  12. Patricia Santofimia‐Castaño · 3 shared papers, 2020–2025 · strength 0.49
  13. Jonathan Garnier · 2 shared papers, 2026 · strength 0.42
  14. Odile Gayet · 3 shared papers, 2020–2022 · strength 0.39
  15. Ana Sahores · 2 shared papers, 2023–2026 · strength 0.35
  16. Raul A. Urrutia · 2 shared papers, 2015–2025 · strength 0.29
  17. Gwen Alyce Lomberk · 2 shared papers, 2015–2025 · strength 0.29
  18. Julie Roques · 2 shared papers, 2020–2022 · strength 0.26
  19. Matías Estarás · 1 shared paper, 2025 · strength 0.25
  20. Pascal R. Hammel · 1 shared paper, 2026 · strength 0.21
  21. Emma Folch‐Puy · 2 shared papers, 2015–2021 · strength 0.19
  22. Daniel Closa · 2 shared papers, 2015–2021 · strength 0.19
  23. Betina González · 1 shared paper, 2023 · strength 0.14
  24. Carlos Alberto Davio · 1 shared paper, 2023 · strength 0.14
  25. Rémy Nicolle · 1 shared paper, 2021 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.